Published in Exp Cell Res on July 01, 2004
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res (2007) 0.96
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis (2006) 0.91
A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J (2007) 0.89
The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol (2009) 0.82
Targeted alpha therapy approach to the management of pancreatic cancer. Cancers (Basel) (2011) 0.80
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer. J Biol Chem (2011) 0.78
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions. Sci Rep (2016) 0.75
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene (2017) 0.75
In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg Med Chem (2006) 2.15
Trigger for group A streptococcal M1T1 invasive disease. FASEB J (2006) 1.77
An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J Med Chem (2007) 1.57
N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg Med Chem (2008) 1.56
Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer (2008) 1.55
Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol (2005) 1.34
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem (2008) 1.21
The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues. J Bacteriol (2006) 1.13
Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation. FASEB J (2008) 1.12
Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect Immun (2004) 1.09
Bacterial plasminogen receptors: mediators of a multifaceted relationship. J Biomed Biotechnol (2012) 0.99
Identification of the 49-kDa autoantigen associated with lymphocytic hypophysitis as alpha-enolase. J Clin Endocrinol Metab (2002) 0.97
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res (2007) 0.96
Activin A is essential for neurogenesis following neurodegeneration. Stem Cells (2009) 0.96
The maintenance of high affinity plasminogen binding by group A streptococcal plasminogen-binding M-like protein is mediated by arginine and histidine residues within the a1 and a2 repeat domains. J Biol Chem (2006) 0.95
Divergence in the plasminogen-binding group a streptococcal M protein family: functional conservation of binding site and potential role for immune selection of variants. J Biol Chem (2005) 0.95
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer (2011) 0.94
The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. J Biol Chem (2006) 0.90
A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J (2007) 0.89
Cell surface antigens of Mycoplasma species bovine group 7 bind to and activate plasminogen. Infect Immun (2003) 0.87
Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma. Semin Thromb Hemost (2011) 0.86
P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta (2010) 0.83
Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice. Anticancer Res (2013) 0.82
The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol (2009) 0.82
Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett (2011) 0.81
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog (2013) 0.80
Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions. Thromb Haemost (2008) 0.79
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. Recent Pat Anticancer Drug Discov (2008) 0.79
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand. Bioorg Med Chem (2011) 0.79
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorg Med Chem Lett (2011) 0.78
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer. J Biol Chem (2011) 0.78
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol Cancer Ther (2007) 0.78
Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes. Thromb Haemost (2010) 0.78
Synthesis and hydrolytic evaluation of acid-labile imine-linked cytotoxic isatin model systems. Bioorg Med Chem (2011) 0.78
Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM). Biochim Biophys Acta (2010) 0.77
The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil. Anticancer Drugs (2013) 0.77
Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing. J Innate Immun (2013) 0.77
Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anticancer Drugs (2011) 0.76
The plasminogen activation system in pathology: use in prognosis and therapy. Curr Drug Targets (2011) 0.76
5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor. J Med Chem (2016) 0.76
Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery. Pharm Res (2014) 0.75
Erratum to: Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery. Pharm Res (2015) 0.75
Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Anticancer Drugs (2009) 0.75
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro. Bioorg Med Chem Lett (2010) 0.75
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer. Cancer Lett (2011) 0.75